The Abili-T Phase IIb study evaluating Opexa’s Tcelna immunotherapy as a treatment for secondary progressive MS (SPMS) is nearing completion. The firm is fully funded to Phase IIb data, which are expected in early Q416 and, if positive, could sharply increase investor and stakeholder interest. Merck, the marketer of MS drug Rebif (interferon beta-1a), has an option to in-license Tcelna in MS. Our rNPV is $37.7m (vs $35.1m previously); after including $7.0m Q216 net cash, this gives an e
29 Jun 2016
Moving closer towards Abili-T data in SPMS
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Moving closer towards Abili-T data in SPMS
- Published:
29 Jun 2016 -
Author:
Pooya Hemami -
Pages:
8
The Abili-T Phase IIb study evaluating Opexa’s Tcelna immunotherapy as a treatment for secondary progressive MS (SPMS) is nearing completion. The firm is fully funded to Phase IIb data, which are expected in early Q416 and, if positive, could sharply increase investor and stakeholder interest. Merck, the marketer of MS drug Rebif (interferon beta-1a), has an option to in-license Tcelna in MS. Our rNPV is $37.7m (vs $35.1m previously); after including $7.0m Q216 net cash, this gives an e